BioMedNewsBreaks Archive - Page 77 of 249

WednesdayApr 17, 2024 2:17 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as Multiple Sclerosis Treatment Presented at AAN Conference

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., announced that results from a phase 2 Visionary-MS long-term extension (“LTE”) study have been presented at the 2024 American Academy of Neurology (“AAN”) annual meeting. The data, which demonstrates improved clinical, functional and structural outcomes associated with daily oral dosing of CNM-Au8 30 mg. for up to three years of treatment, was presented by Dr. Michael Barnett, MBBS, FRACP, FRCP, PhD, from the University of Sydney. The new long-term results from the clinical trial indicate the repair and remyelinating effects of CNM-Au8 treatment in…

WednesdayApr 17, 2024 1:42 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) in Process of Responding to Emergency Request for IV Suramin from African Health Ministry

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has received an urgent request from the Ministry of Health (“MOH”) of Malawi requesting emergency access to IV suramin. According to the announcement, Malawi officials requested the suramin in efforts to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used in that region of Africa; the drug is used specifically to treat the most severe form of African sleeping sickness. Last week, PaxMedica completed execution of its three pivotal registration/validation batches of PAX-101 (an IV form of suramin) in preparation for a…

TuesdayApr 16, 2024 1:32 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on additional preclinical data for INM-089, a proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 (“CB1”) and cannabinoid receptor 2 (“CB2”). The reported data continues to demonstrate positive pharmacological effects in the treatment of dry age-related macular degeneration (“AMD”). According to the announcement, in vivo preclinical studies in AMD disease models show that INM-089 delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement. Earlier results showed that INM-089 also preserved retinal function…

MondayApr 15, 2024 1:33 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company advancing its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization, recently appointed Amy Mahery to its board of directors. “A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and large companies in common and rare conditions, as well as across several therapeutic areas… Ms. Mahery lauded CNS Pharmaceuticals and its efforts to fill gaps in areas with high unmet medical needs, such as glioblastoma multiforme (‘GBM’) treatment, saying,…

MondayApr 15, 2024 10:55 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Update on Celly Nu Investment

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is reporting on its investment in Celly Nutrition Corp. According to the report, FSA entered into a loan-amending agreement with Celly Nu that increased the principal of a previously announced term loan by $300,000, from $1 million to $1.3 million. Celly Nu is a privately held Canadian company launching an innovative beverage product that can assist in expediting alcohol metabolism and faster recovery from alcohol consumption. The announcement noted that the…

FridayApr 12, 2024 1:00 pm

BioMedNewsBreaks — Sigyn Therapeutics Inc. (SIGY) Leveraging Portfolio to Overcome Current Limitations in Healthcare

Sigyn Therapeutics (OTCQB: SIGY), a medical technology that creates medical solutions to treat life-threatening conditions, is developing a portfolio of technologies, including Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM) and ImmunePrep(TM), which have each been designed to overcome a current limitation in healthcare. “As it relates to pathogen-associated disorders, the company has advanced Sigyn Therapy(TM) from concept through product development and subsequently completed five invitro blood purification studies, which validated the ability of Sigyn Therapy(TM) to extract 12 different therapeutic targets from human blood plasma. As a result of these study outcomes, Sigyn Therapy is a candidate to treat a wide range of…

FridayApr 12, 2024 12:55 pm

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Closes on Public Offering Valued at Estimated $5.2M

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has closed on its previously announced public offering. The offering was comprised of up to 2,234,043 shares of Class A LGVN common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 2,234,043 shares of Class A common stock, both offered at $2.35 per share and associated warrant. The announcement noted that the warrants are exercisable upon issuance for up to five years. The public offering resulted in gross…

FridayApr 12, 2024 11:42 am

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Announces ‘Milestone Achievement’ on Journey to Developing PAX-101

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has completed the execution of three pivotal registration/validation batches of PAX-101, which is an IV formulation of suramin. According to the announcement, this is an important milestone achievement as the company works toward enabling a New Drug Application (“NDA”) submission to the U.S. Food and Drug Administration (“FDA”). Currently, the company anticipates submitting the NDA in Q4 2024; this will mark another key milestone as the company works toward the potential commercial availability in the United States of the first and only form of suramin for…

ThursdayApr 11, 2024 3:03 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Looking to Advance Discussions for Accelerated Approval, New NDA for CNM-Au8(R) in 2024

Clene (NASDAQ: CLNN), alongside its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. These include amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “Clene’s lead candidate, CNM-Au8(R), is a gold nanocrystal suspension that has emerged as a promising candidate for the treatment of both ALS and MS… Despite the FDA’s decision in late 2023 against allowing Clene to move forward with an accelerated approval pathway based on initial biomarker data, Clene is diligently preparing supplemental data to provide additional supportive biomarker, survival and mechanistic…

WednesdayApr 10, 2024 2:12 pm

BioMedNewsBreaks — OneMedNet Corporation (NASDAQ: ONMD) Moves to Solidify Cash Position, Accelerate Growth

OneMedNet (NASDAQ: ONMD) is the leading curator of regulatory-grade Real World Data (“iRWD(TM)”) through its proven OneMedNet iRWD(TM) solution. The company recently announced that it has entered into a definitive securities purchase agreement, dated as of March 28, 2024, with an institutional investor providing up to $4.54 million in funding through a private placement for the issuance of senior convertible notes. OneMedNet intends to use the net proceeds from the offering for working capital purposes. “This securities purchase agreement demonstrates confidence in our comprehensive iRWD(TM) platform, marking an important milestone for OneMedNet as we have the investment needed to expedite…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as Multiple Sclerosis Treatment Presented at AAN Conference

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) in Process of Responding to Emergency Request for IV Suramin from African Health Ministry

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD

BioMedNewsBreaks — CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Update on Celly Nu Investment

BioMedNewsBreaks — Sigyn Therapeutics Inc. (SIGY) Leveraging Portfolio to Overcome Current Limitations in Healthcare

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Closes on Public Offering Valued at Estimated $5.2M

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Announces ‘Milestone Achievement’ on Journey to Developing PAX-101

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Looking to Advance Discussions for Accelerated Approval, New NDA for CNM-Au8(R) in 2024

BioMedNewsBreaks — OneMedNet Corporation (NASDAQ: ONMD) Moves to Solidify Cash Position, Accelerate Growth

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search